Terns Pharmaceuticals Inc expected to post a loss of 29 cents a share - Earnings Preview

Terns Pharmaceuticals

09/05/2025 16:36

Terns Pharmaceuticals Inc TERN.OQ TERN.O is expected to show no change in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Terns Pharmaceuticals Inc is for a loss of 29 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 13.8% in the last three months. ​

Wall Street's median 12-month price target for Terns Pharmaceuticals Inc is $20.00​, above​ its last closing price of $3.00. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.28
-0.28
-0.26
Beat
7.1
Dec. 31 2025
-0.34
-0.31
-0.24
Beat
22.6
Sep. 30 2024
-0.32
-0.32
-0.28
Beat
12.6​
Jun. 30 2024
-0.34
-0.34
-0.31
Beat
8.8
​​Mar. 31 2024
-0.34
-0.34
-0.30
Beat
11.1
Dec. 31 2023
-0.29
-0.29
-0.29
Met
0.8​
Sep. 30 2023
-0.31
-0.31
-0.42
Missed
-37.5
Jun. 30 2023
-0.34
-0.34
-0.25
Beat
26.2

This summary was machine generated May 9 at 15:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)